Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous Calcitonin for Preventing Postherpetic Neuralgia in Acute Herpes Zoster
NCT07655804Phase 3Recruiting
- Sponsor
- Tanta University
- Start
- Jul 2026
- Primary completion
- Apr 2027
- Countries
- 1
01
Overview
Phase 3, randomised trial of TBRIA in herpes zoster (HZ) (2 arms), sponsored by Tanta University. Primary endpoint: Incidence of postherpetic neuralgia at 3 months. Started Jul 2026; status: recruiting.
02
Drugs
TBRIA
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on NCT07655804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07655804.